Prognostic Role of MicroRNA 222 in Patients with Glioma: A Meta-analysis

Table 3

Summary of meta-analysis results.

Stratified study	Data sets	Pooled HR (95% CI)	value	Heterogeneity
					value
OS	7	1.72 (1.31-2.26)	<0.001	73.00%	0.001
DFS	4	1.02 (0.86-1.22)	0.807	65.90%	0.032
Country
China	4	1.90 (1.10-3.26)	0.021	70.70%	0.017
USA	3	1.61 (1.16-2.22)	0.004	79.20%	0.008
Material
Tissue	6	1.58 (1.22-2.04)	0.001	66.50%	0.011
Blood	1	2.81 (1.7-4.65)	0.0001	—	—
Stage
IV	4	1.47 (1.11-1.94)	0.007	73.70%	0.01
I-IV	3	2.53 (1.76-3.63)	<0.001	0.00%	0.82
Method
Q-PCR	3	1.79 (0.90-3.57)	0.099	78.80%	0.009
Immunohistochemistry scoring	1	2.39 (1.15-4.96)	0.02	—	—
Sample size
>100	4	1.47 (1.12-1.94)	0.01	73.70%	0.007
<100	3	2.53 (1.76-3.63)	<0.001	0.00%	0.82

HR: hazard ratio; CI: confidence interval; Q-PCR: quantitative polymerase chain reaction; IHC: immunohistochemistry.